August 21, 2024
Press & Media
Tackling SARS-CoV-2 Variant Challenges: PlexBio's πCode Technology Advances Intelli-OVI as Next-Generation Molecular Diagnostic Tool
On August 9, 2024, Communications Medicine published a paper on a novel method for detecting SARS-CoV-2 variants developed using PlexBio’s technology and products (Volume 4, Article number: 161, https://www.nature.com/articles/s43856-024-00582-z). This detection method, named "Intelli-OVI," was developed by a joint research team from Kumamoto University, Tokyo Metropolitan Institute of Public Health, and Kumamoto Health Science University in Japan.
According to the published paper, Intelli-OVI combines PlexBio’s πCode technology, the IntelliPlex system, and the OVI (Objective Variant Identification) computational program to rapidly and easily detect both known and novel mutations of SARS-CoV-2.
The study demonstrated that Intelli-OVI can be upgraded to respond to emerging variants by adding or modifying DNA probes. The latest version has successfully validated the simultaneous use of 35 different probes, effectively identifying over 20 different SARS-CoV-2 variants. Furthermore, when new virus mutations emerge, Intelli-OVI can quickly and easily detect the possibility of new variants by indicating abnormal test results. Based on these results, "Intelli-OVI" can be upgraded to respond to those rapidly evolving viruses like SARS-CoV-2 though further validation is required for future applications.
Intelli-OVI, leveraging PlexBio's πCode technology and IntelliPlex system, offers several advantages over the NGS whole genome sequencing technology. These include rapid detection, high-throughput capabilities for processing large sample volumes, simplified operation with lower technical barriers, and significantly reduced testing costs. Moreover, Intelli-OVI's ability to be rapidly upgraded to address new variants demonstrates its immense potential as an innovative molecular diagnostic tool.
The COVID-19 pandemic has led to a dramatic loss of human life worldwide and presents an unprecedented challenge to public health. To date, SARS-CoV-2 variants continue to evolve and trigger outbreaks across the globe. Keeping track of the overwhelming number of new sequences and the growing number of data sources to against new variants has become a tremendous task.
The innovative research, using SARS-CoV-2 as a successful example, suggests a new generation molecular diagnostic tool as well as the immense potential applications of πCode technology for various viral infections. We are glad to expect the Intelli-OVI utilizes our technology to enhance global pandemic response capabilities to detect disease faster, identify outbreaks sooner and contributes to the public health.
We look forward to collaborating with researchers and institutions from various fields to fully utilize the unlimited potential of PlexBio's technology and platforms in developing innovative solutions. If you are interested in applying our technology and platforms, we sincerely invite you to contact us through our company's official website (https://www.plexbio.com).
According to the published paper, Intelli-OVI combines PlexBio’s πCode technology, the IntelliPlex system, and the OVI (Objective Variant Identification) computational program to rapidly and easily detect both known and novel mutations of SARS-CoV-2.
The study demonstrated that Intelli-OVI can be upgraded to respond to emerging variants by adding or modifying DNA probes. The latest version has successfully validated the simultaneous use of 35 different probes, effectively identifying over 20 different SARS-CoV-2 variants. Furthermore, when new virus mutations emerge, Intelli-OVI can quickly and easily detect the possibility of new variants by indicating abnormal test results. Based on these results, "Intelli-OVI" can be upgraded to respond to those rapidly evolving viruses like SARS-CoV-2 though further validation is required for future applications.
Intelli-OVI, leveraging PlexBio's πCode technology and IntelliPlex system, offers several advantages over the NGS whole genome sequencing technology. These include rapid detection, high-throughput capabilities for processing large sample volumes, simplified operation with lower technical barriers, and significantly reduced testing costs. Moreover, Intelli-OVI's ability to be rapidly upgraded to address new variants demonstrates its immense potential as an innovative molecular diagnostic tool.
The COVID-19 pandemic has led to a dramatic loss of human life worldwide and presents an unprecedented challenge to public health. To date, SARS-CoV-2 variants continue to evolve and trigger outbreaks across the globe. Keeping track of the overwhelming number of new sequences and the growing number of data sources to against new variants has become a tremendous task.
The innovative research, using SARS-CoV-2 as a successful example, suggests a new generation molecular diagnostic tool as well as the immense potential applications of πCode technology for various viral infections. We are glad to expect the Intelli-OVI utilizes our technology to enhance global pandemic response capabilities to detect disease faster, identify outbreaks sooner and contributes to the public health.
We look forward to collaborating with researchers and institutions from various fields to fully utilize the unlimited potential of PlexBio's technology and platforms in developing innovative solutions. If you are interested in applying our technology and platforms, we sincerely invite you to contact us through our company's official website (https://www.plexbio.com).
